A new era begins for Remedica with the appointment of new CEO, Andrew Bird, signalling a renewed focus on global expansion, operational excellence, and long-term strategic development.

Andrew brings with him a wealth of leadership experience and a strong track record in the pharmaceutical and healthcare industry, having held several senior roles over the past two decades.

With his deep industry knowledge, strategic mindset and forward-thinking leadership, Andrew’s appointment marks a new and exciting chapter of growth for Remedica, as we continue to strengthen our global presence and build on our commitment to delivering high-quality, accessible pharmaceutical solutions.

In Andrew’s words: ‘I’m happy to join a company with a strong legacy of purpose and a team deeply committed to making a positive change in people’s lives around the world. I look forward to working with everyone at Remedica to build on that foundation, push the boundaries and continue to leverage our strengths to create real change in the pharma industry.’

With strong leadership and a clear sense of direction, Remedica is all set to shape the future of healthcare, improving patients’ outcomes worldwide.